Ovarian reserve after chemotherapy in children: First results of a prospective cohort study

Abstract STUDY QUESTION How does ovarian reserve in children decline according to the cumulative equivalent doses of cyclophosphamide (CED) received? SUMMARY ANSWER Anti-Müllerian Hormone (AMH) levels decrease significantly during treatment across all CED doses groups, remaining persistently reduced in high-risk patients while fully recovering in low- and medium-risk patients. WHAT IS KNOWN ALREADY Fertility counselling guidelines are mainly based on adolescent and adult data, with limited evidence on treatment gonadotoxicity in children diagnosed with cancer, particularly those who are prepubertal. STUDY DESIGN, SIZE AND DURATION CHANCE (CHildren, AMH, caNCEr) is an ongoing prospective multicentre cohort study enrolling children aged 3–14 years at cancer diagnosis in France and Belgium. This analysis focuses on 173 patients diagnosed with cancer between 2014 and 2025 who have at least one year of post-treatment follow-up. PARTICIPANTS, SETTING, METHODS All young girls diagnosed with cancer between 3 and 14 years of age were recruited in the study. Exclusion criteria included prior chemotherapy, central nervous system tumours or irradiation, ovarian disease or surgery (except fertility preservation procedure), familial premature ovarian insufficiency (POI), and severe chronic illness. Among the 173 enrolled patients, 105 were eligible for analysis. Patients were categorized according to CED: < 4 000mg/m2(low-risk, n = 64), 4 000 to 8 000mg/m2 (medium-risk, n = 15) and > 8 000mg/m2 and/or total body or pelvic irradiation (high-risk, n = 26). Factors related to reproductive issues–including hormonal profiles, pubertal development, and fertility preservation strategies–were recorded. Assessments were performed at baseline, after treatment, and throughout follow-up until 18 years of age. The incidence of POI – defined as induced puberty and/or Follicle-Stimulating Hormone (FSH) ≥25IU/l during follow-up and/or absence of menstrual resumption after treatment in post-pubertal patients–and ovarian reserve assessed by AMH level were analysed according to CED, age and diseases, and fertility preservation strategies. MAIN RESULTS AND THE ROLE OF CHANCE Mean (SD) age at diagnosis was 8.4 ±4 years. POI occurred only in high-risk patients (46.1%) and was associated with higher CED (p = 0.0006), underlying disease type (p = 0.005) but not age at diagnosis. AMH levels significantly decline during treatment in all groups; complete recovery occurs in low- and medium-risk patients. While AMH levels significantly increase during the follow-up in low-risk group, they remain stable in moderate risk group. In high-risk patients, AMH levels remained significantly lower throughout the follow-up compared with baseline, as confirmed by repeated-measures analysis, with 80% of the patients presenting values below 0.5 ng/ml. Fertility preservation was performed in 4.7%, 20% and 57.7% in low, medium and high-risk groups, respectively. In the high-risk group, POI incidence was higher in patients who underwent ovarian cryopreservation alone (n = 7) than in those without fertility preservation procedure (n = 11) (85.7 versus 18.2%; p = 0.01), despite lower CED exposure. LIMITATIONS, REASONS FOR CAUTION This is a first non-powered analysis of the prospective CHANCE cohort. The results warrant confirmation in the final analysis, once the entire population reaches 18 years of age. WIDER IMPLICATIONS OF THE FINDINGS Our findings highlight the need for strengthening fertility preservation counselling in high-risk patients, while carefully balancing individual risks and benefits. This interim analysis suggests that longitudinal monitoring should be proposed over fertility preservation at diagnosis for low-risk patients and may represent an appropriate strategy also for medium-risk prepubertal children. FUNDING The study was supported by a grant from the Fondation Roi Baudoin (Fonds Lokumo) and Fonds Genicot. ID supported by the FNRS (Fond National de la Recherche Scientifique) as Senior Associate Researcher. DISCLOSURES The authors have nothing to disclosure related to this study TRIAL REGISTRATION NUMBER ClinicalTrial.gov NCT02595255

Authors

Institutions

Publication Details

Journal
Human Reproduction Open
Published
2026-11-17
DOI
https://doi.org/10.1093/hropen/hoag103
Primary Topic
Reproductive Biology and Fertility
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ovarian reserve after chemotherapy in children: First results of a prospective cohort study

Lucie Rouffiange, Alina Ferster, Judith Racapé, Isabelle Demeestere et al.
Human Reproduction Open
Reproductive Biology and Fertility
article

Ovarian reserve after chemotherapy in children: First results of a prospective cohort study

Lucie Rouffiange, Alina Ferster, Judith Racapé, Isabelle Demeestere, Christine Decanter, Hélène Sudour‐Bonnange, Veerle Labarque, Julie Dechène, Camille Grysole, Christine Devalck, Bénédicte Bruno, Safiatou Diallo
article en

Abstract

Abstract STUDY QUESTION How does ovarian reserve in children decline according to the cumulative equivalent doses of cyclophosphamide (CED) received? SUMMARY ANSWER Anti-Müllerian Hormone (AMH) levels decrease significantly during treatment across all CED doses groups, remaining persistently reduced in high-risk patients while fully recovering in low- and medium-risk patients. WHAT IS KNOWN ALREADY Fertility counselling guidelines are mainly based on adolescent and adult data, with limited evidence on treatment gonadotoxicity in children diagnosed with cancer, particularly those who are prepubertal. STUDY DESIGN, SIZE AND DURATION CHANCE (CHildren, AMH, caNCEr) is an ongoing prospective multicentre cohort study enrolling children aged 3–14 years at cancer diagnosis in France and Belgium. This analysis focuses on 173 patients diagnosed with cancer between 2014 and 2025 who have at least one year of post-treatment follow-up. PARTICIPANTS, SETTING, METHODS All young girls diagnosed with cancer between 3 and 14 years of age were recruited in the study. Exclusion criteria included prior chemotherapy, central nervous system tumours or irradiation, ovarian disease or surgery (except fertility preservation procedure), familial premature ovarian insufficiency (POI), and severe chronic illness. Among the 173 enrolled patients, 105 were eligible for analysis. Patients were categorized according to CED: < 4 000mg/m2(low-risk, n = 64), 4 000 to 8 000mg/m2 (medium-risk, n = 15) and > 8 000mg/m2 and/or total body or pelvic irradiation (high-risk, n = 26). Factors related to reproductive issues–including hormonal profiles, pubertal development, and fertility preservation strategies–were recorded. Assessments were performed at baseline, after treatment, and throughout follow-up until 18 years of age. The incidence of POI – defined as induced puberty and/or Follicle-Stimulating Hormone (FSH) ≥25IU/l during follow-up and/or absence of menstrual resumption after treatment in post-pubertal patients–and ovarian reserve assessed by AMH level were analysed according to CED, age and diseases, and fertility preservation strategies. MAIN RESULTS AND THE ROLE OF CHANCE Mean (SD) age at diagnosis was 8.4 ±4 years. POI occurred only in high-risk patients (46.1%) and was associated with higher CED (p = 0.0006), underlying disease type (p = 0.005) but not age at diagnosis. AMH levels significantly decline during treatment in all groups; complete recovery occurs in low- and medium-risk patients. While AMH levels significantly increase during the follow-up in low-risk group, they remain stable in moderate risk group. In high-risk patients, AMH levels remained significantly lower throughout the follow-up compared with baseline, as confirmed by repeated-measures analysis, with 80% of the patients presenting values below 0.5 ng/ml. Fertility preservation was performed in 4.7%, 20% and 57.7% in low, medium and high-risk groups, respectively. In the high-risk group, POI incidence was higher in patients who underwent ovarian cryopreservation alone (n = 7) than in those without fertility preservation procedure (n = 11) (85.7 versus 18.2%; p = 0.01), despite lower CED exposure. LIMITATIONS, REASONS FOR CAUTION This is a first non-powered analysis of the prospective CHANCE cohort. The results warrant confirmation in the final analysis, once the entire population reaches 18 years of age. WIDER IMPLICATIONS OF THE FINDINGS Our findings highlight the need for strengthening fertility preservation counselling in high-risk patients, while carefully balancing individual risks and benefits. This interim analysis suggests that longitudinal monitoring should be proposed over fertility preservation at diagnosis for low-risk patients and may represent an appropriate strategy also for medium-risk prepubertal children. FUNDING The study was supported by a grant from the Fondation Roi Baudoin (Fonds Lokumo) and Fonds Genicot. ID supported by the FNRS (Fond National de la Recherche Scientifique) as Senior Associate Researcher. DISCLOSURES The authors have nothing to disclosure related to this study TRIAL REGISTRATION NUMBER ClinicalTrial.gov NCT02595255

Human Reproduction Open
Université Libre de Bruxelles (BE), Inserm (FR), Universitair Ziekenhuis Leuven (BE), Erasmus Hospital (BE), Centre Hospitalier Universitaire de Lille (FR), Centre Hospitalier Chrétien (BE), VIB-KU Leuven Center for Cancer Biology (BE), Hôpital Jeanne de Flandre (FR), Centre Oscar Lambret (FR), Onco Lille (FR), Université Lille Nord de France (FR), KU Leuven (BE)
Reproductive Biology and Fertility
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon